RNA Interference as Therapeutics for Hepatocellular Carcinoma

Author(s): Chuanrui Xu, Susie A. Lee, Xin Chen

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 6 , Issue 1 , 2011

Become EABM
Become Reviewer
Call for Editor


Hepatocellular carcinoma (HCC), a major form of primary liver cancer, is one of the leading causes of cancer related deaths worldwide. Hepatitis B and C infections are major risk factors for the development of HCC. Currently, the treatment options are rather limited, and the prognosis for this malignancy is poor for most of these patients. RNA interference has emerged as an innovative technology for gene silencing and as a potential therapeutic for various diseases, including cancer. HCC has been widely chosen as a model system for the development of RNAi therapy due to the convenience and availability of effective delivery of RNA molecules into liver tissues. Targets for HCC treatment include HBV and HCV viruses, oncogenes, as well as cellular genes mediating angiogenesis, tumor growth and metastasis. Here, we summarized the progress of RNAi therapeutics in HCC treatment, relevant patents, potential challenges and prospects in the future.

Keywords: HCC, RNAi, Hepatocellular carcinoma, aflatoxin B1, Akt signaling, hepatocarcinogenesis, VEGFR, Drosha's cleavage, transcriptional gene silencing, RISC, TERT, IRES, DICER1, cadherin-17, STAT3, TGFBR, FoxM1B, CIAPIN1, metalloprotease, Transferrin, ALN-VSP02, SNALPs

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [106 - 115]
Pages: 10
DOI: 10.2174/157489211793980097

Article Metrics

PDF: 28